BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31190860)

  • 1. Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.
    Wu Q; Zhang B; Sun Y; Xu R; Hu X; Ren S; Ma Q; Chen C; Shu J; Qi F; He T; Wang W; Wang Z
    Onco Targets Ther; 2019; 12():3545-3563. PubMed ID: 31190860
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gastric cancer.
    Wu Q; Zhang B; Wang Z; Hu X; Sun Y; Xu R; Chen X; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Xue Q; Zhou YL
    Pathol Res Pract; 2019 May; 215(5):1038-1048. PubMed ID: 30975489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising novel biomarkers and candidate small-molecule drugs for lung adenocarcinoma: Evidence from bioinformatics analysis of high-throughput data.
    Li C; Wan Y; Deng W; Fei F; Wang L; Qi F; Zheng Z
    Open Med (Wars); 2022; 17(1):96-112. PubMed ID: 35028418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis.
    Ni M; Liu X; Wu J; Zhang D; Tian J; Wang T; Liu S; Meng Z; Wang K; Duan X; Zhou W; Zhang X
    Front Genet; 2018; 9():469. PubMed ID: 30369945
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of key candidate tumor biomarkers in non-small-cell lung cancer by
    Chen W; Zhu S; Zhang Y; Xiao J; Tian D
    Oncol Lett; 2020 Jan; 19(1):1008-1016. PubMed ID: 31897214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of key genes associated with non-small-cell lung cancer.
    Ma Q; Xu Y; Liao H; Cai Y; Xu L; Xiao D; Liu C; Pu W; Zhong X; Guo X
    J Cell Physiol; 2019 Dec; 234(12):22742-22752. PubMed ID: 31127628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
    Liu X; Liu X; Li J; Ren F
    Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of hub biomarkers and pathways in lung cancer and prognostic evaluation.
    Yin Y; Li D; He M; Wang J
    Transl Cancer Res; 2022 Aug; 11(8):2622-2635. PubMed ID: 36093542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promising novel biomarkers and candidate small molecule drugs in kidney renal clear cell carcinoma: Evidence from bioinformatics analysis of high-throughput data.
    Zhang B; Wu Q; Wang Z; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qin L; Ma Q; Zhou YL
    Mol Genet Genomic Med; 2019 May; 7(5):e607. PubMed ID: 30793530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.
    Zhao M; Li X; Chen X
    J Bioenerg Biomembr; 2021 Apr; 53(2):177-189. PubMed ID: 33538941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of hub genes associated with prognosis in non-small cell lung cancer by integrated bioinformatics analysis.
    Zeng Y; Li N; Chen R; Liu W; Chen T; Zhu J; Zeng M; Cheng J; Huang J
    Transl Cancer Res; 2020 Nov; 9(11):7149-7164. PubMed ID: 35117319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of estrogen receptor-associated hub genes and potential molecular mechanisms in non-smoking females with lung adenocarcinoma using integrated bioinformatics analysis.
    Wang H; Zhang Z; Xu K; Wei S; Li L; Wang L
    Oncol Lett; 2019 Nov; 18(5):4605-4612. PubMed ID: 31611968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of key differentially expressed mRNAs and microRNAs in non-small cell lung cancer using bioinformatics analysis.
    Wang W; Wang S; Pan L
    Exp Ther Med; 2020 Oct; 20(4):3720-3732. PubMed ID: 32855723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of genes and pathways leading to poor prognosis of non-small cell lung cancer using integrated bioinformatics analysis.
    Cui S; Lou S; Feng J; Tang X; Xiao X; Huang R; Guo W; Zhou Y; Huang F
    Transl Cancer Res; 2022 Apr; 11(4):710-724. PubMed ID: 35571642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis.
    Yu L; Liang X; Wang J; Ding G; Tang J; Xue J; He X; Ge J; Jin X; Yang Z; Li X; Yao H; Yin H; Liu W; Yin S; Sun B; Sheng J
    Genet Res (Camb); 2023; 2023():6782732. PubMed ID: 36688087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Molecular Mechanism of the Drug-Treated Breast Cancer Based on Gene Expression Microarray.
    Alshabi AM; ; Shaikh IA; Vastrad C
    Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31311202
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of Hub Genes as Potential Prognostic Biomarkers in Cervical Cancer Using Comprehensive Bioinformatics Analysis and Validation Studies.
    Xue H; Sun Z; Wu W; Du D; Liao S
    Cancer Manag Res; 2021; 13():117-131. PubMed ID: 33447084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel candidate genes and small molecule drugs in ovarian cancer by bioinformatics strategy.
    Wei M; Bai X; Dong Q
    Transl Cancer Res; 2022 Jun; 11(6):1630-1643. PubMed ID: 35836518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
    Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
    J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and verification of hub genes associated with the progression of non-small cell lung cancer by integrated analysis.
    Mengyan X; Kun D; Xinming J; Yutian W; Yongqian S
    Front Pharmacol; 2022; 13():997842. PubMed ID: 36176446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.